Jonathan Romanowsky, MBA- Commercial Strategy Advisor
Jonathan has over 20 years of healthcare strategy and commercialization experience, including nearly 15 years focused on launching and promoting novel molecular diagnostics based on RNA expression profiling. He has led marketing, reimbursement, sales and commercial teams for CardioDx and CareDx, Veracyte, Telomere Diagnostics, and Inflammatix.
Amanda Elam, PhD- Business Operations Advisor
Amanda has 20 years of experience in entrepreneurship research and practice across various industries. She is President and co-founder of an RTP-based molecular diagnostics firm, Galaxy Diagnostics, and holds a research appointment in entrepreneurship, innovation, and women leadership at Babson College. Since inception Amanda has been advising HealthSpan Diagnostics on various aspects of business development and growth, operational considerations, and fundraising.
Peter McCullough, MD, MPH
Dr. McCullough is a Vice Chief of Medicine at Baylor University Medical Center and directs cardiovascular education and research for the Baylor Health Care System. Dr. McCullough is a cardiologist and an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state, with over 1000 publications including the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. In 2013, he was honored with the International Vicenza Award for Critical Care Nephrology for his outstanding contribution and dedication to the emerging problem of cardiorenal syndromes. Dr. McCullough is the current Chair of the National Kidney Foundation’s Kidney Early Evaluation Program (KEEP), the nation’s largest community screening effort for chronic diseases.
Paul M. Palevsky, MD
Dr. Palevsky is a Professor of Clinical & Translational Science, University of Pittsburgh and a thought leader in the field of prevention and treatment of AKI. He was the study chair of the VA/NIH Acute Renal Failure Trial Network (ATN) study evaluating intensity of renal replacement therapy in critically ill patients with acute kidney injury, and he currently serves as co-chair of the PRESERVE trial, evaluating the comparative effectiveness of saline and bicarbonate and the efficacy of N-acetylcysteine in preventing kidney damage following angiography.